Abstract
Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.
Original language | English (US) |
---|---|
Pages (from-to) | 375-393 |
Number of pages | 19 |
Journal | PET Clinics |
Volume | 10 |
Issue number | 3 |
DOIs | |
State | Published - Jul 1 2015 |
Keywords
- Computed tomography
- Fluorodeoxyglucose
- PET
- Patient management
- Skeletal sarcoma
- Soft tissue sarcoma
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging